COVID-19 AstraZeneca vaccine and extremely rare blood clots and translations

This updated factsheet contains important information on the risks and benefits of the COVID-19 AstraZeneca vaccine following reports of a very rare side effect more than 4 days and within 28 days after vaccination. Over the age of 40, the benefits of this vaccine outweigh any potential risk associated with this rare condition. It is important that if you have had one dose of this vaccine with no serious side effects, that you continue to get the second dose with the same vaccine.

COVID-19 AstraZeneca vaccine and extremely rare blood clots is available in BSL and ISL:

• BSL
• ISL

A large print accessible version of this leaflet is available below as a Word document. Braille versions of this leaflet are available from Trust vaccination centres or by contacting Michelle.McKibbin@HSCNI.net. An audio version of the leaflet is also available.